Effectiveness, safety and tolerability of gatifloxacin, a new 8-methoxyfluoroquinolone, in the treatment of outpatients with community-acquired pneumonia: a Brazilian study

Franca, Suelene Aires; Carvalho, Carlos Roberto Ribeiro

doi:10.1590/s1413-86702002000400002

Cited by 5 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The high rate of clinical cure that we found (98%) is similar to the rate of cure found in other, phase III and IV studies made with gatifloxacin for the treatment of PAC [12][13][14][15][16].…”

Section: Discussionsupporting

confidence: 89%

An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers

Nicodemo¹

2003

Braz J Infect Dis

View full text Add to dashboard Cite

We made an open label, multicenter, non-comparative study to assess the efficacy and safety of oral gatifloxacin, 400mg PO given once-daily during 7 to 14 days for the treatment of adult outpatients with community-acquired pneumonia at five Brazilian medical facilities. Among the 86 subjects available for clinical evaluation, 84 (98%) were cured. The bacteriological eradication and presumed eradication rate was 98% (52/53) among the 44 (51%) patients who were bacteriologically evaluated. Drug-related adverse events were reported by 27% of the patients, diarrhea being the most frequent, occurring in 12% of patients. Adverse events were considered mild (89%) or moderate (11%). We conclude that a 7-14 day course of gatifloxacin, 400mg PO given once daily is safe and effective for the treatment of community-acquired pneumonia. The drug had a favorable safety profile and a good clinical and bacteriological efficacy.

show abstract

Section: Discussionsupporting

confidence: 89%

An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers

Nicodemo¹

2003

Braz J Infect Dis

View full text Add to dashboard Cite

show abstract

“…The incidence of pneumonia in the Latin American region is substantial, however pneumonia is generally not considered to be a reportable disease, and only estimations of the number of annual cases have been made. In countries with the most available data, 120 000 annual cases (Argentina), 13 170 000 annual cases (Chile), 14 and 1 920 000 annual cases (Brazil) 15,16 have been estimated.…”

Section: Incidencementioning

confidence: 99%

“…18 A prospective study of 84 patients in five Latin American countries (Argentina, Brazil, Chile, Mexico, and Uruguay) showed that 50-52.8% of CAP patients were admitted to the hospital. 12,15,16 This high rate of hospitalization increases the economic burden of CAP through utilization of more expensive health care resources and contrasts with the rest of the world, where 80% of CAP patients are treated as outpatients. 15 In a retrospective study in Argentina that assessed 436 patients admitted to 12 hospitals, 30% were admitted to the intensive care unit (ICU).…”

Section: Hospitalizationsmentioning

confidence: 99%

Clinical and economic burden of pneumonia among adults in Latin America

Istúriz

Luna

Ramirez

2010

International Journal of Infectious Diseases

View full text Add to dashboard Cite

The clinical and economic burden of adult community-acquired pneumonia (CAP) in Latin America is not well known. We conducted a literature review to describe the etiology, incidence, hospitalization, morbidity and mortality, antibiotic resistance, costs associated with care, and the potential benefits of pneumococcal vaccination in the reduction of adult CAP in Latin America. Data that were published during the period from January 1970 through August 2008 were identified via the Web sites and databases of the Pan American Health Organization, Latin American health agencies, and the US National Institutes of Health, National Library of Medicine (MEDLINE). Streptococcus pneumoniae was identified as the most common pathogen, accounting for up to 35% of CAP cases. The mean rate of CAP due to penicillin-resistant S. pneumoniae was 39%. The mortality in Latin America due to lower respiratory tract infections has been reported to be 6%, compared with 4% in developed regions, and CAP was the third most frequent cause of death in adults in 31 Latin American countries in 2001-2003. Although S. pneumoniae caused the majority of CAP, similar to other regions of the world, mortality due to CAP in Latin America was substantially greater than that in developed countries. This review demonstrates the need to facilitate standardized surveillance and reporting systems to monitor the burden of CAP and to implement prevention strategies to decrease the clinical and economic burden of CAP in Latin American adults.

show abstract

“…Apesar da incidência da pneumonia ser expressiva na região, a doença, em geral, não é de notificação obrigatória, portanto, apenas estimativas são publicadas. Foram estimados 120 mil casos anuais de PAC na Argentina, 170 mil no Chile e 1,92 bilhão no Brasil[21][22][23].…”

unclassified

Revisão sistemática de estudos de avaliação econômica da vacinação universal em adultos acima de 60 anos de idade com a vacina pneumocócica polissacarídea 23-valente

Nishikawa¹

View full text Add to dashboard Cite

Revisão sistemática de estudos de avaliação econômica da vacinação universal em adultos acima de 60 anos de idade com a vacina pneumocócica polissacarídea 23-valente Dissertação apresentada à Faculdade de Medicina da Universidade de São Paulo para obtenção do título de Mestre em Ciências Programa de Medicina Preventiva Orientadora: Profa. Dra. Patrícia Coelho de Soárez São Paulo 2018 Dedico esta dissertação aos meus avós, Seiichi Nishikawa, Sumi Nishikawa, Akira Matsumoto e Kimiko Matsumoto, que saíram de sua terra natal e batalharam muito para que seus netos tivessem sucesso, honra e orgulho de suas escolhas. A minha mãe, Kayoko Matsumoto, por sempre exigir o meu melhor e pela ajuda incondicional. A minha mestra Tamie Kitahara, pelos ensinamentos de vida e pela dedicação que sempre teve comigo. Ao mestre Tadashi Komesu, que com muita energia positiva sempre me ensinou que devemos seguir em frente, na alegria e na tristeza. Agradecimentos Durante o período do mestrado, foram muitas as alegrias e tristezas, assim como acontece em toda nossa existência. Nesta caminhada, sempre contei com o apoio de diversas pessoas, que doaram o que tinham de si para tornar mais esse passo possível. Meus sinceros votos de agradecimento à professora Dra. Patrícia Coelho de Soárez, minha orientadora, por todo o profissionalismo, paciência e compreensão ao longo deste percurso. Agradeço com toda sinceridade, pelo seu tempo e entusiasmo, mesmo em momentos difíceis, e por sempre me aguardar com um sorriso em cada etapa do projeto. À professora Dra. Ana Marli Christovan Sartori, pelo apoio incondicional e ensinamentos. À Giulia Marcelino Mainardi, pelo importante trabalho e parceria como segunda revisora do presente estudo. Aos alunos do grupo, Tania Yuba, Juliana Kodaira Viscondi e Roseli Fernandes, pela companhia e momentos de descontração, que possibilitaram a jornada ser mais leve e divertida. ABSTRACT Nishikawa AM. Systematic review of economic evaluations of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in individuals 60 years of age or older [dissertation]. São Paulo: "Faculdade de Medicina, Universidade de São Paulo"; 2018. INTRODUCTION: Infections caused by Streptococcus pneumoniae are one of the main causes of morbidity and mortality in the world, particularly in developing countries, generating a significant clinical and economic impact. Children under 2 years old, adults ³60 years old and populations with cronic conditions are the most affected populations.Due to the increase in antibiotic resistance and the increase of the disease's consequences, primary prevention of the disease is being discussed with antipneumococcal vaccination as one of the most effective public health strategies in reducing the burden of the disease. OBJECTIVE: To systematically review and evaluate the quality of the reported economic evaluation studies of the 23-valent pneumococcal polysaccharide vaccine in the elderly immunization with the aim to compare the different methodological strategies adopted by the published studies and discuss ...

show abstract

Effectiveness, safety and tolerability of gatifloxacin, a new 8-methoxyfluoroquinolone, in the treatment of outpatients with community-acquired pneumonia: a Brazilian study

Cited by 5 publications

References 17 publications

An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers

An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers

Clinical and economic burden of pneumonia among adults in Latin America

Revisão sistemática de estudos de avaliação econômica da vacinação universal em adultos acima de 60 anos de idade com a vacina pneumocócica polissacarídea 23-valente

Contact Info

Product

Resources

About